Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54661
Title: Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
Authors: 
Filiation: Hospital Universitario de Fuenlabrada. Servicio de Aparato Digestivo
Keywords: 
Mesh: 
Decs: 
Issue Date: 2022
Publisher: SAGE Publications
Citation: Argüelles-Arias F, Bermejo F, Borrás-Blasco J, Domènech E, Sicilia B, Huguet JM, de Arellano AR, Valentine WJ, Hunt B. Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therap Adv Gastroenterol. 2022 May 9;15:17562848221086131. doi: 10.1177/17562848221086131. PMID: 35574429; PMCID: PMC9092579.
Abstract: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM), and iron sucrose (IS).
PMID: 35574429
URI: https://hdl.handle.net/20.500.12530/54661
Rights: info:eu-repo/semantics/openAccess
Atribución-NoComercial-CompartirIgual 3.0 España
ISSN: 1756-283X
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
17562848221086131.pdf146.69 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons